Sign In
Last checked at 
2 Dec 2021 10:20
Feedback plc
Director Dealings
London, UK, 02 December 2021 - Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist clinical communication company, announces that further to the Fundraising, details of which were announced on 2 November 2021 and Admission which occurred on 30 November 2021, the following Directors' dealings as part of the Placing and Open Offer have completed:
Rory Shaw, Non Executive Chairman, has subscribed for 1,441,859 New Ordinary Shares through the Open Offer at the Issue Price of 0.7 pence per Ordinary Share.
Philipp Prince, Non Executive Director, has subscribed for 1,546,543 New Ordinary Shares through the Open Offer at the Issue Price of 0.7 pence per Ordinary Share.
Adam Denning, Non-Executive Director, has subscribed for 1,428,570 New Ordinary Shares through the Placing at the Issue Price of 0.7 pence per Ordinary Share.
Details of the Ordinary Shares held by these Directors are detailed in the table below:
Director/ PDMR | Position | Existing interest in Ordinary Shares | Ordinary Shares purchased | Total beneficial interest in Ordinary Shares | Total interest in Company's issued share capital |
Rory Shaw | Non-Executive Chairman | 9,818,780 | 1,441,859 | 11,260,639 | 0.4% |
Philipp Prince | Non-Executive Director | 2,500,000 | 1,546,543 | 4,046,543 | 0.2% |
Adam Denning | Non-Executive Director | 1,530,411 | 1,428,570 | 2,958,981 | 0.1% |
The notification set out below, provides further details of such dealings:
1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
a)
| Names
| Rory Shaw Philipp Prince Adam Denning | |||
2
| Reason for the notification
| ||||
a)
| Position/status
| Non-Executive Chairman Non-Executive Director Non-Executive Director | |||
b)
| Initial notification /Amendment
| Initial notification | |||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
| Name
| Feedback plc | |||
b)
| LEI
| 213800UGOF2GT2U2RV90 | |||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
a)
| Description of the financial instrument, type of instrument | Ordinary Shares of 0.25 pence each in Feedback plc | |||
Identification code | GB0003340550 | ||||
b)
| Nature of the transaction
| Purchase of Ordinary Shares | |||
c)
| Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
0.7p | 1,441,859 | ||||
0.7p | 1,546,543 | ||||
0.7p | 1,428,570 | ||||
d)
| Aggregated information | ||||
- Aggregated volume | n/a | ||||
- Price | |||||
e)
| Date of the transaction
| 30 November 2021 | |||
f)
| Place of the transaction | XLON | |||
The capitalised terms used in this announcement have the same meanings as in the announcement published by the Company at 7.01 a.m. on 2 November 2021 unless otherwise stated.
Enquiries:
Feedback plc Tom Oakley, CEO Anesh Patel, CFO | +44 (0)1954 718072 IR@fbk.com |
Panmure Gordon (UK) Limited (NOMAD and Broker) Emma Earl/Freddy Crossley (Corporate Finance) Rupert Dearden (Corporate Broking) | +44 (0)20 7886 2500 |
Walbrook PR Ltd | Tel: 020 7933 8780 or feedbackplc@walbrookpr.com |
Paul McManus/Nick Rome/Nicholas Johnson | 07980 541 893 or 07748 325 236 or 07884 664 686 |
Notes to Editors
Feedback plc (AIM: FDBK) is a pioneer of regulated clinical communication products. Its core product, Bleepa, is a revolutionary medical imaging communications app, providing an easy-to-use, high quality tool to enable remote and secure communications between front-line clinicians and teams. Importantly, it is the only CE marked medical imaging communications platform on the NHSx clinical communications tools framework. Bleepa has unparalleled functionality for everyday practice and can be accessed from any internet-connected device, enabling control of patient cases when on the go.
Its highly scalable Software as a Service ("SaaS") based revenue model will provide increasing levels of visibility as the Company grows its customer base. With a growing distribution base and technology in place, the focus is on leveraging key relationships in order to drive sales both in the UK and internationally to all forms of care providers. As a fully certified medical device, Bleepa aims to disrupt the medical imaging communications market and, importantly, increase the accuracy and speed of clinical review.
Follow the stocks
